1 / 9

Sofosbuvir-Velpatasvir in Genotype 3 ASTRAL-3

Explore ASTRAL-3 trial findings on Sofosbuvir-Velpatasvir treatment in Genotype 3 HCV patients. Discover dosing, efficacy, and safety of SOF-VEL regimen versus SOF+RBV. Published study in New England Journal of Medicine.

plee
Download Presentation

Sofosbuvir-Velpatasvir in Genotype 3 ASTRAL-3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 TreatmentNaïve & Experienced Sofosbuvir-Velpatasvir in Genotype 3ASTRAL-3 *Published in tandem with ASTRAL-2 Trial Foster GR, et al. N Engl J Med. 2015;373:2608-17.

  2. Sofosbuvir-Velpatasvir in HCV Genotype 3ASTRAL-3: Study Features Source: Foster GR, et al. N Engl J Med. 2015;373:2608-17.

  3. Sofosbuvir-Velpatasvir in HCV Genotype 3ASTRAL-3: Study Design 0 12 24 36 Week Treatment-naïve or experienced GT 3 (N=552) SOF-VEL N=277 SVR12 SOF + RBV N=275 SVR12 *Randomization stratified by treatment experience and cirrhosis status. Abbreviations: SOF-VEL = sofosbuvir-velpatasvir; RBV = ribavirin Drug DosingSofosbuvir-velpatasvir (400/100 mg): fixed-dose combination; one pill once dailySofosbuvir: 400 mg once dailyRibavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Foster GR, et al. N Engl J Med. 2015;373:2608-17.

  4. Sofosbuvir-Velpatasvir in HCV Genotype 3ASTRAL-3: Baseline Characteristics Source: Foster GR, et al. N Engl J Med. 2015;373:2608-17.

  5. Sofosbuvir-Velpatasvir in HCV Genotype 3ASTRAL-3: Results ASTRAL-3: SVR12 Results 264/277 221/275 264/277 221/275 P<0.001 for superiority of Sofosbuvir-Velpatasvir compared with Sofosbuvir + Ribavirin Source: Foster GR, et al. N Engl J Med. 2015;373:2608-17.

  6. Sofosbuvir-Velpatasvir in HCV Genotype 3ASTRAL-3: Results ASTRAL-3: SVR12 Results by Cirrhosis & Treatment Experience 160/163 141/156 40/43 33/45 31/34 22/31 33/37 22/38 Treatment Naïve Treatment-Experienced Source: Foster GR, et al. N Engl J Med. 2015;373:2608-17.

  7. Sofosbuvir-Velpatasvir in HCV Genotype 3ASTRAL-3: Resistance Baseline NS5A Resistance-Associated Variants and SVR12 Total, n=274 100 97% SVR12 90 88% SVR12 80 84% No BL NS5A RAVs N=231 70 60 16% BLNS5A RAVs N=43 SVR12 (%) 50 40 30 20 10 38/43 225/231 0 • SVR12 was 84% (21/25) in patients with Y93H Source: Foster GR, et al. N Engl J Med. 2015;373:2608-17.

  8. Sofosbuvir-Velpatasvir in HCV Genotype 3ASTRAL-3: Adverse Events Source: Foster GR, et al. N Engl J Med. 2015;373:2608-17.

  9. Sofosbuvir-Velpatasvir in HCV Genotype 3ASTRAL-3: Conclusions Source: Foster GR, et al. N Engl J Med. 2015;373:2608-17.

More Related